Back to User profile » Dr Michael C. Mosier
Papers published by Dr Michael C. Mosier:
Original Research
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/AZY3gSe4gVw/1.jpg)
Navari RM, Mosier MC
OncoTargets and Therapy 2019, 12:3277-3284
Published Date: 30 April 2019
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N
Cancer Management and Research 2017, 9:179-187
Published Date: 19 May 2017